Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain.
Auteur : Parcq J, Bertrand T, Baron AF, Hommet Y, Anglès-Cano E, Vivien D
Année : 2013
Journal : J Thromb Haemost 1538-7836
PubMed Id : 23301636
Thrombolysis with tissue-type plasminogen activator (t-PA) is the only treatment approved for acute ischemic stroke. Although t-PA is an efficient clot lysis enzyme, it also causes damage to the neurovascular unit, including hemorrhagic transformations and neurotoxicity.